Stock DNA
Pharmaceuticals & Biotechnology
CNY 16,416 Million (Mid Cap)
25.00
NA
1.06%
0.06
5.19%
2.88
Revenue and Profits:
Net Sales:
1,084 Million
(Quarterly Results - Sep 2025)
Net Profit:
80 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
244.37%
0%
244.37%
6 Months
212.66%
0%
212.66%
1 Year
254.52%
0%
254.52%
2 Years
133.3%
0%
133.3%
3 Years
100.9%
0%
100.9%
4 Years
55.63%
0%
55.63%
5 Years
89.19%
0%
89.19%
Zhende Medical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.71%
EBIT Growth (5y)
-26.44%
EBIT to Interest (avg)
50.41
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
0.67
Tax Ratio
17.09%
Dividend Payout Ratio
44.94%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
36.27%
ROE (avg)
21.96%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
1.64
EV to EBIT
29.69
EV to EBITDA
16.42
EV to Capital Employed
1.64
EV to Sales
2.17
PEG Ratio
0.17
Dividend Yield
1.88%
ROCE (Latest)
5.51%
ROE (Latest)
6.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
1,084.10
1,108.60
-2.21%
Operating Profit (PBDIT) excl Other Income
87.50
162.30
-46.09%
Interest
11.80
7.80
51.28%
Exceptional Items
-2.10
1.30
-261.54%
Consolidate Net Profit
79.90
78.20
2.17%
Operating Profit Margin (Excl OI)
80.80%
81.80%
-0.10%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -2.21% vs 11.80% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 2.17% vs 49.24% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,247.90
4,113.40
3.27%
Operating Profit (PBDIT) excl Other Income
602.60
459.60
31.11%
Interest
31.60
30.90
2.27%
Exceptional Items
-21.10
-74.80
71.79%
Consolidate Net Profit
397.20
213.40
86.13%
Operating Profit Margin (Excl OI)
83.50%
52.30%
3.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 3.27% vs -32.68% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 86.13% vs -69.59% in Dec 2023
About Zhende Medical Co., Ltd. 
Zhende Medical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






